Abstracts tagged "Randomized Trial"

Abstract Number: 0122 • ACR Convergence 2021
Clinical Impact of a Digital Behavioral Therapy for Fibromyalgia Management: A Randomized Controlled Trial
Stephanie Catella¹, Michael Gendreau², Nicolette Vega¹, Allison Kraus¹, Michael Rosenbluth¹, Sherry Soefje³, Shishuka Malhotra⁴ and Lesley Arnold⁵, ¹Swing Therapeutics, San Francisco, CA, ²Gendreau Consulting, LLC, Poway, CA, ³Excell Research, Oceanside, CA, ⁴Neuro-Behavioral Clinical Research, North Canton, OH, ⁵University of Cincinnati, Cincinnati, OH
Background/Purpose: Recommendations for fibromyalgia management include both pharmacologic and nonpharmacologic treatments. Cognitive behavioral therapy (CBT) has demonstrated level 1A evidence for fibromyalgia management, though access…
Abstract Number: 0837 • ACR Convergence 2021
Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
Peter Nash¹, Arthur Kavanaugh², Maya Buch³, Bernard Combe⁴, Louis Bessette⁵, In-Ho Song⁶, Tim Shaw⁷, Yanna Song⁶, Jessica Suboticki⁶ and Roy Fleischmann⁸, ¹Griffith University, Brisbane, Australia, ²University of California San Diego, La Jolla, CA, ³University of Leeds, Leeds, United Kingdom, ⁴CHU Montpellier Montpellier University, Montpellier, France, ⁵Laval University, Québec City, QC, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) or low disease activity (LDA).1,2 A greater proportion…
Abstract Number: 1926 • ACR Convergence 2021
Effectiveness of the Making It Work™ Program at Improving Absenteeism in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial
Andre Luquini¹, Yufei Zheng², Hui Xie², Catherine L. Backman³, Pamela Rogers⁴, Alex Kwok⁴, Astrid Knight⁴, Monique Gignac⁵, Dianne Mosher⁶, Linda Li³, John Esdaile⁷, Carter Thorne⁸ and Diane Lacaille², ¹University of British Columbia / Arthritis Research Canada, Fort Saint John, BC, Canada, ²Arthritis Research Canada, Richmond, BC, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada / UBC, Vancouver, BC, Canada, ⁵Institute for Work & Health, Toronto, ON, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Arthritis Research Canada, Vancouver, BC, Canada, ⁸Southlake Regional Health Centre, Newmarket, ON, Canada
Background/Purpose: Despite advances in treatment, absenteeism remains a major problem for workers living with inflammatory arthritis (IA), leading to reduced income and quality of life.…
Abstract Number: 0183 • ACR Convergence 2021
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Results from the Phase 3, Randomized, Double-blind Clinical Trial for CsDMARD-IR and Bio-IR Patients
Merav Lidar¹, Jacob Aelion², Gareth Scott Tarr³, Kim Papp⁴, Lisa Barcomb⁵, Ahmed M. Soliman⁵, Wenjing Lu⁶, Ann Eldred⁵ and Andrew Ostor⁷, ¹Chaim Sheba Medical Center, Ramat Gan, Israel, ²Arthritis Clinic and West Tennessee Research Institute, Jackson, TN, ³Winelands Medical Research Centre and the Institute of Orthopaedics and Rheumatology (IOR), Winelands Medi-Clinic Orthopaedic Hospital, Stellenbosch, South Africa, ⁴K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ⁵Abbvie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, ⁷Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia
Background/Purpose: Risankizumab (RZB) is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. RZB is being investigated…
Abstract Number: 0924 • ACR Convergence 2021
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Désirée van der Heijde¹, Atul Deodhar², Walter Maksymowych³, Joachim Sieper⁴, Filip Van den Bosch⁵, Tae-Hwan Kim⁶, Mitsumasa Kishimoto⁷, Andrew Ostor⁸, Bernard Combe⁹, Yunxia Sui¹⁰, Yuanyuan Duan¹¹, Alvina D. Chu¹¹ and In-Ho Song¹², ¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²Oregon Health & Science University, Portland, OR, ³Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁹Montpellier University, Montpellier, France, ¹⁰AbbVie, North Chicago, IL, ¹¹AbbVie Inc, North Chicago, ¹²AbbVie Inc., North Chicago, IL
Background/Purpose: The objective of this long-term analysis of the SELECT-AXIS 1 study was to report safety and efficacy of upadacitinib (UPA) in active AS through…
Abstract Number: 1940 • ACR Convergence 2021
Malignancies in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors
Jeffrey Curtis¹, Kunihiro Yamaoka², Yi-Hsing Chen³, Levent M Gunay⁴, Naonobu Sugiyama⁵, Carol A Connell⁶, Cunshan Wang⁶, Joseph Wu⁶, Sujatha Menon⁶, Ivana Vranic⁷ and Juan J Gomez-Reino⁸, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²School of Medicine, Department of Rheumatology and Infectious Diseases, Kitasato University, Sagamihara, Japan, ³Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ⁴Pfizer Inc, Istanbul, Turkey, ⁵Pfizer Japan Inc, Tokyo, Japan, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Tadworth, Surrey, United Kingdom, ⁸Hospital Clínico Universitario, Santiago de Compostela, Spain
Background/Purpose: ORAL Surveillance (NCT02092467) was a post-authorization safety study to assess the relative risk of tofacitinib vs TNF inhibitors (TNFi), based on observed increases in…
Abstract Number: 0193 • ACR Convergence 2021
Tocilizumab for the Treatment of Familial Mediterranean Fever – a Randomized, Double Blind, Placebo-controlled Phase II Study
Jorg Henes¹, Sebastian Saur², David Kofler³, Martin Krusche⁴, Theodoros Xenitidis⁵, Christoph Meisner⁶, Claudia Kedor⁷, Ina Koetter⁸, Hendrik Schulze-Koops⁹ and Eugen Feist¹⁰, ¹University Hospital Tuebingen, Tuebingen, Germany, ²Universtiy Hostpiatl Tübingen, Tuebingen, Germany, ³Division of Rheumatology and Clinical Immunology, Department I of Internal Medicine; University Hospital Cologne, Cologne, Germany, ⁴Charite Berlin, Berlin, Germany, ⁵University Hospital Tuebingen, Rheumatology, Tuebingen, Germany, ⁶University Tuebingen, Statistics, Tuebingen, Germany, ⁷Charite University Hospital Berlin, Berlin, Germany, ⁸University Hospital Hamburg Eppendorf, Hamburg, Germany, ⁹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ¹⁰Helios Department of Rheumatology, Vogelsang-Gommern, Germany
Background/Purpose: Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease characterized by chronic inflammation, recurrent episodes of fever, abdominal and thoracic pain due to…
Abstract Number: 0957 • ACR Convergence 2021
Vitamin D and Marine n-3 Fatty Acid Supplementation and Prevention of Autoimmune Disease in the VITAL Randomized Controlled Trial
Jill Hahn¹, Nancy Cook², Erik Alexander³, Sonia Friedman³, Vadim Bubes³, Joseph Walter³, Gregory Kotler³, I-Min Lee³, JoAnn Manson³ and Karen Costenbader⁴, ¹Harvard T.H. Chan School of Public Health, Boston, MA, ²Brigham and Womens' Hospital, Boston, MA, ³Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁴Brigham and Women's Hospital, Belmont, MA
Background/Purpose: In observational studies, vitamin D has been inconsistently associated with reduced risk of several autoimmune diseases, and a large randomized, controlled trial has been…
Abstract Number: 0441 • ACR Convergence 2021
A Randomized, Double-blind, Placebo-controlled Study of Arimoclomol in Patients with Inclusion Body Myositis
Pedro Machado¹, Richard Barohn², Michael McDermott³, Thomas Blaetter⁴, Tom Lloyd⁵, Aziz Shaibani⁶, Miriam Freimer⁷, Anthony Amato⁸, Emma Ciafaloni³, Sarah Jones⁹, Tahseen Mozaffar¹⁰, Summer Gibson¹¹, Matthew Wicklund¹², Todd Levine¹³, Claus Sundgreen⁴, Tim Carstensen⁴, Karen Bonefeld⁴, Anders Jørgensen⁴, Karina Phonekeo⁴, Andrew Heim¹⁴, Laura Herbelin¹⁴, Michael Hanna¹⁵ and Mazen Dimachkie¹⁴, ¹Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ²University of Missouri - Columbia, Columbia, MO, ³University of Rochester, Rochester, NY, ⁴Orphazyme A/S, Copenhagen, Denmark, ⁵Johns Hopkins University, Baltimore, MD, ⁶Nerve and Musle Center, Houston, TX, ⁷Ohio State University, Columbus, OH, ⁸Brigham and Women's Hospital, Boston, MA, ⁹University of Virginia, Charlottesville, VA, ¹⁰University of California Irvine, Irvine, CA, ¹¹University of Utah, Salt Lake City, UT, ¹²University of Colorado, Denver, CO, ¹³Phoenix Neurological Associates, Phoenix, AZ, ¹⁴University of Kansas Medical Center, Kansas City, KS, ¹⁵University College London, London, United Kingdom
Background/Purpose: Inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. Since immune suppression has…
Abstract Number: 1212 • ACR Convergence 2021
Prediction of 1-Year Intravenous Abatacept Retention in Patients with RA Using Novel Machine Learning Techniques: Directionality and Importance of Predictors
Rieke Alten¹, Claire Behar², Christine Boileau³, Pierre Merckaert⁴, Ebenezer Afari⁵, Virginie Vannier-Moreau⁶, Anael Ohayon⁶, Sean Connolly⁷, Aurelie Najm⁸, Pierre Antoine Juge⁹, Gengyuan Liu⁷, Angshu Rai¹⁰, Yedid Elbez¹¹ and Karissa Lozenski⁷, ¹Schlosspark-Klinik University, Berlin, Germany, ²Tulsy, Paris, France, ³Excelya, Boulogne-Billancourt, France, ⁴Data Revenue GmbH, Berlin, Germany, ⁵Private Practice, Brunoy, France, ⁶Bristol Myers Squibb, Rueil-Malmaison, France, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Institute of Infection, Immunity and Inflammation, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁹Hopital Bichat-Claude Bernard, Service de Rhumatologie, Paris, France, ¹⁰Bristol Myers Squibb (at the time of analysis), Princeton, NJ, ¹¹Deepscover, Puteaux, France
Background/Purpose: In the ACTION study (NCT02109666), previous multivariable Cox proportional-hazards regression models showed that predictors of 1-year retention to intravenous abatacept treatment included: patient global…
Abstract Number: 0453 • ACR Convergence 2021
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 24-Week Integrated Results from 2 Phase 3, Randomized, Double-blind Clinical Trials for CsDMARD-IR and Bio-IR Patients
Andrew Ostor¹, Kim Papp², Mireia Moreno³, Cathy Spargo⁴, Lisa Barcomb⁵, Ahmed M. Soliman⁵, Wenjing Lu⁶, Ann Eldred⁵ and Lars Erik Kristensen⁷, ¹Monash University, Cabrini Hospital, and Emertius Research, Melbourne, Australia, ²K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, ³Rheumatology Department, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí, Universitat Autònoma de Barcelona, Barcelona, Spain, ⁴Vincent Pallotti Hospital, Johannesburg, South Africa, ⁵Abbvie Inc., North Chicago, IL, ⁶AbbVie Inc., North Chicago, ⁷The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Frederiksberg, Denmark
Background/Purpose: Risankizumab (RZB) is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. RZB is being investigated…
Abstract Number: 1290 • ACR Convergence 2021
Validation of a Novel Lupus Multivariable Outcome Score as an Outcome Measure for Systemtic Lupus Erythematosus Trials
Michal Abrahamowicz¹ and Peter Lipsky², ¹McGill University, Montréal, QC, Canada, ²AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Development of effective new Systemic Lupus Erythematosus (SLE) treatments requires a validated responder index responsive to clinically meaningful change and relevant to clinical practice.…
Abstract Number: 0488 • ACR Convergence 2021
Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
Philip Mease¹, Philip S Helliwell², Paula Silwinska-Stanczyk³, Malgorzata Miakisz⁴, Andrew Ostor⁵, Elena Peeva⁶, Michael Vincent⁶, Vanja Sikirica⁷, Randall Winnette⁸, Ruolun Qiu⁶, Gang Li⁷, Gang Feng⁶, Jean Beebe⁶ and David Martin⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³REUMATIKA – Centrum Reumatologii NZOZ, Warsaw, Poland, ⁴Twoja Przychodnia Centrum Medyczne Nowa Sol, Nowa Sol, Poland, ⁵Monash University, Cabrini Hospital & Emeritus Research, Melbourne, Australia, ⁶Pfizer Inc, Cambridge, MA, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, New York, NY
Background/Purpose: Brepocitinib is a small-molecule tyrosine kinase 2/Janus kinase 1 inhibitor that has shown promising results in an oral formulation for plaque psoriasis and alopecia…
Abstract Number: 1359 • ACR Convergence 2021
Risk of Respiratory Tract Infections with Biologic and Targeted Synthetic Antirheumatic Agents in Psoriatic Arthritis: A Systematic Review and Network Meta-analysis
Yi-Shao Liu¹, Jawad Bilal², Muhammad Ajmal², Syed Arsalan Ahmed Naqvi³, Zaina Shahid⁴, Kaneez Zahra Rubab Khakwani², Farva Gondal⁵, Irbaz Bin Riaz⁶, Sandipan Bhattacharjee¹, Roxanne Bogucka¹ and C. Kent Kwoh⁷, ¹University of Texas at Austin, Austin, TX, ²University of Arizona, Tucson, AZ, ³Dow University of Health Sciences, Karachi, Pakistan, ⁴Lehigh Valley Health Network, Allentown, PA, ⁵University of Arizona College of Medicine, Tucson, AZ, ⁶Mayo Clinic, Phoenix, AZ, ⁷University of Arizona College of Medicine, Tuscon, AZ
Background/Purpose: A variety of biologic and targeted synthetic disease modifying antirheumatic agents have been widely used among patients with psoriatic arthritis (PsA). Due to the…
Abstract Number: 0496 • ACR Convergence 2021
Safety and Efficacy of Rituximab for Systemic Sclerosis: A Double-Blind, Parallel-Group Comparison, Investigators Initiated Confirmatory Randomized Clinical Trial (DESIRES Study)
Satoshi Ebata¹, Ayumi Yoshizaki¹, Koji Oba², Kosuke Kashiwabara³, Keiko Ueda³, Yukari Umemura⁴, Takeyuki Watadani⁵, Takemichi Fukasawa¹, Shunsuke Miura¹, Asako Yoshizaki-Ogawa¹, Yoshihide Asano¹, Naoko Okiyama⁶, Masanari Kodera⁷, Minoru Hasegawa⁸ and Shinichi Sato¹, ¹Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Biostatistics, School of Public Health, Graduate School of Medicine, and Interfaculty Initiative in Information Studies, The University of Tokyo, Tokyo, Japan, ³Clinical Research Support Center, The Tokyo University Hospital, Tokyo, Japan, ⁴Biostatistics Section, Department of Data Science, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan, ⁵Department of Diagnostic Radiology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan., Tokyo, Japan, ⁶Department of Dermatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Ibaraki, Japan, ⁷Department of Dermatology, Japan Community Health Care Organization Chukyo Hospital, Aichi, Japan., Aichi, Japan, ⁸Department of Dermatology, Division of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan., Fukui, Japan
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease belonging to collagen diseases, characterized by fibrosis of various organs including the skin and lungs, and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].